RET and thyroid gland carcinoma: The safety profile reported in this analysis is consistent with previously reported results in patients with RET fusion–positive NSCLC and thyroid cancer from the ARROW study10,11, with no new safety signals identified, and no effect of pralsetinib on QT interval was observed11.